Schrödinger, Inc. (SDGR) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript

Group 1 - The company's mission is to develop a computational platform that enables researchers in life sciences and material sciences to design better molecules more rapidly and efficiently [2] - The traditional drug discovery process involves trial and error, which is time-consuming and has a high failure rate [3] - The goal of the computationally driven approach is to replace experimental methods in drug discovery, thereby optimizing the process [3]